The HCPLive Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for C difficile, IBS and IBD, Crohn's disease, and more.
April 19th 2024
In recognition of World IBS Day, we spoke with Jeffrey Roberts about what led him to found the holiday in 2019 and took a closer look at the continued marginalization of the condition.
Show Me the Data: Bridging Clinical Gaps in Later Lines of Metastatic CRC… It’s Easy as VEGFR1, 2, 3!
April 17, 2024
View More
9th Annual School of Gastrointestinal Oncology® (SOGO®)
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
Rapid Oncology Abstract Review®: Key Updates in Gastrointestinal Cancers from the ASCO Annual Meeting
View More
Medical Crossfire®: Bridging Precision Medicine Techniques and Emerging Treatments in Metastatic Colorectal Cancer
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
Burst CME: Incorporating the Latest Updates in IBS Treatment into Your Practice
View More
Advancing Care in Erosive Esophagitis: Towards a Path of Complete Healing
View More
Oncology Town Hall: Live Report from Barcelona for Advances in the Treatment of GI Cancers
View More
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Community Practice Connections™: 20th Annual Meeting of the International Society of Gastrointestinal Oncology®
View More
Working Group: Streamlining the Pathway from Diagnosis to Treatment in Inflammatory Bowel Disease
View More
Advances In™: The Evolving Role of VEGFR in the Treatment of Refractory mCRC
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Show Me the Data: Bridging Clinical Gaps in Later Lines of Metastatic CRC… It’s Easy as VEGFR1, 2, 3!
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Tissue Stewardship and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
IBD Trials Re-Randomizing Patients Had Higher Remission Rates
In recent years trial designs have evolved to become increasingly complex and sophisticated with new endpoints that could include patient-reported outcomes, biomarkers, mucosal, and histological healing, central endoscopy reading, and trials that examine both induction and maintenance of remission within the same study.
Intercept Cancels Plans For NASH Treatment After CRL
The treatment, developed by Intercept Pharmaceuticals, could not be approved in its present form, according to the CRL and any resubmission of the treatment for patients with NASH would require at least the successful completion of the long-term outcomes phase of the REGENERATE study.
Patients With Hepatitis Delta Virus More Likely to Experience Rapid Liver Fibrosis Progression
Patients with anti-HDV antibodies had a significantly higher prevalence of liver cirrhosis, significantly lower prothrombin time, and a higher prevalence of HIV co-infection compared to patients who demonstrated serum anti-HDV antibody negatively.